BerGenBio

Pre-Annual General Meeting Information • Feb 25, 2021

BERGENBIO ASA: NOTICE OF ANNUAL GENERAL MEETING

BERGENBIO ASA: NOTICE OF ANNUAL GENERAL MEETING

Bergen, Norway - 25 February 2021: BerGenBio ASA (OSE:BGBIO) will be holding its

Annual General Meeting [virtually] on 19 March 2021 at 15:00 hours (CET).

The notice, registration form, power of attorney and proposal from Nomination

Committee are attached to this release. The notice will be sent to all

registered shareholders and is available on the Company's

website: https://www.bergenbio.com/investors/general-meetings/

All shareholders are encouraged to exercise their shareholder rights, either

through advance electronically voting through VPS Investor Services, by

using the enclosed proxy form to provide proxy to the Chairman Sveinung Hole (or

the person he appoints), or to attend the general meeting virtually.

Advance vote or proxy for the Annual General Meeting can be registered through

the company's website or VPS Investor Service within 16 March at 16:00 hours

(CET). Virtual participants need to be logged in to the meeting before 15:00

hours (CET) 19 March 2021.

All shareholders will receive a reference number and pin code required for

registration through the company's website. Reference number and pin code will

be received either by VPS Investor Service or by post depending if the

shareholder is registered as an electronic user.

We encourage all shareholders to register as electronical user in VPS to

save environment impact.

- END -

About?BerGenBio?ASA

BerGenBio?is a clinical-stage biopharmaceutical company focused on developing

transformative drugs targeting AXL as a potential cornerstone of therapy for

aggressive diseases, including immune-evasive, therapy resistant cancers. The

company's proprietary lead candidate,?bemcentinib, is a potentially first-in

-class selective AXL inhibitor in a broad?phase II clinical development

programme focused on combination and single agent therapy in lung cancer,

leukaemia and COVID-19. A first-in-class functional blocking anti-AXL

antibody,?tilvestamab, is undergoing?phase I clinical testing. In

parallel,?BerGenBio?is developing?a?companion diagnostic test to identify

patient populations most likely to benefit from?bemcentinib: this is expected to

facilitate more efficient registration trials supporting a precision medicine

-based commercialisation strategy.

BerGenBio?is based in Bergen, Norway with a subsidiary in Oxford, UK. The

company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more

information, visit?www.bergenbio.com

Contacts

Richard Godfrey, CEO, BerGenBio ASA

+47 917 86 304

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

+47 917 86?513

Forward looking statements

This announcement may contain forward-looking statements, which as such are not

historical facts, but are based upon various assumptions, many of which are

based, in turn, upon further assumptions. These assumptions are inherently

subject to significant known and unknown risks, uncertainties and other

important factors. Such risks, uncertainties, contingencies and other important

factors could cause actual events to differ materially from the expectations

expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.